Blood Res.  2019 Sep;54(3):204-209. 10.5045/br.2019.54.3.204.

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A

• Kim JY
• You CW

• KMID: 2459386
• DOI: http://doi.org/10.5045/br.2019.54.3.204

Abstract

BACKGROUND
Risk factors for the development of inhibitors in previously untreated patients (PUPs) have been reported; this is not the case in previously treated patients (PTPs) owing to fewer studies. Risk factors may differ for the development of PTP versus PUP inhibitors. We aimed to identify risk factors for PTP inhibitor development.
METHODS
Participants were patients at a hemophilia treatment center in Korea with current or past history of factor VIII or factor IX alloantibodies. Observed inhibitors were classified as PUP or PTP inhibitors based on the cumulative number of exposure days. We compared the type and severity of hemophilia, mutation type, and family history of inhibitor between PUPs and PTPs. Events within 3 months before the first inhibitor detection, such as change of the factor concentrate used, short-term high exposure or continuous infusion of factor concentrate, history of surgery, infection, diagnosis of cancer, use of immunosuppressive or immunomodulator agents, and vaccination were compared between PUPs and PTPs.
RESULTS
We observed 5 PUP inhibitors and 5 PTP inhibitors in 115 patients with hemophilia A. Events that might be related to the development of inhibitors within 3 months prior to the first inhibitor detection were observed in all 5 PTPs. On the contrary, no such events were observed in any PUPs. The observed events included a change in the factor concentrate used, subsequent chemotherapy, and short-term high exposure to factor concentrates for controlling hemorrhage and surgeries.
CONCLUSION
Our results suggest a greater role of nongenetic factors in PTP inhibitor development.

Keyword

Hemophilia A; Previously treated patient; Inhibitor; Risk factor

MeSH Terms

Diagnosis
Drug Therapy
Factor IX
Factor VIII
Hemophilia A*
Hemorrhage
Humans
Isoantibodies
Korea
Prevalence*
Risk Factors*
Vaccination
Factor IX
Factor VIII
Isoantibodies

Reference

1. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006; 12:15–22.

2. Saint-Remy JM, Jacquemin MG. Inhibitors to factor VIII: immunology. In : Lee CA, Berntorp EE, Hoots K, editors. Textbook of hemophilia. Chichester, UK: John Wiley & Sons;2014. p. 41–47.

3. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993; 328:453–459.

4. Rothschild C, Laurian Y, Satre EP, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost. 1998; 80:779–783.

5. Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost. 1997; 78:1027–1029.

6. White GC, DiMichele D, Mertens K, et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1999; 81:462.

7. Dimichele DM, Lacroix-Desmazes S, Peyvandi F, Srivastava A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2015; 13:876–879.

8. Goodeve A. The incidence of inhibitor development according to specific mutations and treatment? Blood Coagul Fibrinolysis. 2003; 14:S17–S21.

9. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009; 360:1618–1627.

10. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol. 2005; 130:422–427.

11. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost. 2006; 4:2576–2581.

12. Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost. 2013; 11:1655–1662.

13. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost. 1992; 67:600–602.

14. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007; 110:815–825.

15. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011; 117:6367–6370.

16. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood. 1993; 81:2180–2186.

17. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007; 109:4648–4654.

18. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998; 79:762–766.

19. You CW, Son HS, Kim HJ, Woo EJ, Kim SA, Baik HW. Mutation analysis of factor VIII in Korean patients with severe hemophilia A. Int J Hematol. 2010; 91:784–791.